KCL-HO-1i is a small-molecule, orally bioavailable inhibitor targeting heme oxygenase-1 (HO-1), an enzyme that plays a key role in sustaining immunosuppressive tumor microenvironments by modulating a subset of perivascular tumor-associated macrophages (PvTAMs).
While it has primarily been studied in preclinical models of breast cancer and sarcoma, its mechanism of disrupting HO-1 activity to convert an immunologically “cold” tumor microenvironment into a “hot” one, characterized by increased infiltration of effector CD8+ T cells and enhanced chemotherapy efficacy, makes it highly relevant to prostate cancer.

Prostate cancer shares important features with these models, notably the presence of immunosuppressive TAMs that promote tumor progression, metastasis, and resistance to therapies. HO-1 activity in macrophages supports this immunosuppression, suppressing the local anti-tumor immune response that is critical for controlling disease. Therefore, KCL-HO-1i’s inhibition of HO-1 could potentially reprogram the prostate tumor microenvironment by targeting this macrophage subset, enhancing immune-mediated tumor control and improving the effectiveness of existing treatments such as chemotherapy or immunotherapy.

Though direct studies of KCL-HO-1i in prostate cancer are not yet available publicly, the broader role of HO-1 in prostate cancer pathobiology supports this approach as a promising new therapeutic strategy. Research on tumor-associated macrophages in prostate cancer indicates their substantial role in immune evasion and tumor growth. By inhibiting HO-1 in these macrophages, KCL-HO-1i could reduce the pro-tumoral functions of these immune cells, leading to better immune surveillance and therapeutic responses.

Source.